An injectable ROS-responsive hydrogel comprising chondroitin sulfate@resveratrol liposome package for osteoarthritis alleviation
Biomaterials · 2026-04 · 327 · 123766
DOI: 10.1016/j.biomaterials.2025.123766 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomaterials, 2026-04. Verfasst von Lamei Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Chemo and Biosensing, College of Biology, College of Chemistry and Chemical Engineering, Hunan University, Key Laboratory for…. Hauptthemen laut MEDLINE: Osteoarthritis, Reactive Oxygen Species, Hydrogels, Resveratrol. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Osteoarthritis (OA) is a complex and multifactorial joint disorder. Currently, there are few therapies to slow the progression of OA. Combining symptomatic slow-acting drugs and reactive oxygen species (ROS) scavenging reagents in the inflamed joint shows a promising therapeutic approach for OA. Nonetheless, the short residence time of free drugs in the joint cavity hinders their further application. Herein, an injectable composite of hydrogel and chondroitin sulfate@resveratrol liposome package (Gel/Lip@Res + Chs) was developed to improve drug residency ability and enable the simultaneous delivery of hydrophilic Chs and hydrophobic Res in the joint cavity. This injectable hydrogel, based on phenylboronic acid modified hyaluronic acid (HAPBA) and polyvinyl alcohol (PVA), provided ROS-responsive decomposition property and sustained drug release behavior, thereby effectively scavenging ROS, promoting macrophage repolarization, and decreasing the expression of inflammatory mediators and matrix-degrading enzymes in vitro. As a proof of concept, the in vivo therapeutic efficacy of Gel/Lip@Res + Chs was further examined in both monoiodoacetic acid (MIA)-induced and surgical anterior cruciate ligament transection (ACLT)-induced OA mouse models. Benefiting from the extended residence time of loaded drugs in the joint cavity, the Gel/Lip@Res + Chs treatment could effectively suppress cartilage degeneration and increase the synthesis of the cartilage matrix, thus slowing the advancement of OA. The present study provides a reference for improving drug retention and holds great potential for treating OA-related diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Chemo and Biosensing, College of Biology, College of Chemistry and Chemical Engineering, Hunan University, Key Laboratory for Bio-Nanotechnology and Molecule Engineering of Hunan Province, Changs…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, L., Zhang, M., Zhou, Y., He, L., Chen, M., Wu, Y., Yin, G., He, H., Qi, L., Zhang, B., He, X., & Wang, K. (2026). An injectable ROS-responsive hydrogel comprising chondroitin sulfate@resveratrol liposome package for osteoarthritis alleviation. Biomaterials, 327, 123766. https://doi.org/10.1016/j.biomaterials.2025.123766
Vancouver
Liu L, Zhang M, Zhou Y, He L, Chen M, Wu Y, et al. An injectable ROS-responsive hydrogel comprising chondroitin sulfate@resveratrol liposome package for osteoarthritis alleviation. Biomaterials. 2026;327:123766. doi:10.1016/j.biomaterials.2025.123766
BibTeX
@article{Liu2026,
author = {Liu, Lamei and Zhang, Min and Zhou, Yan and He, Lin and Chen, Mingjian and Wu, Yuchen and Yin, Guanyu and He, Hui and Qi, Lanlin and Zhang, Bin and He, Xiaoxiao and Wang, Kemin},
title = {An injectable ROS-responsive hydrogel comprising chondroitin sulfate@resveratrol liposome package for osteoarthritis alleviation},
journal = {Biomaterials},
year = {2026},
volume = {327},
pages = {123766},
doi = {10.1016/j.biomaterials.2025.123766}
}
EUVIMED